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ProtozoanNovel L-valinate amide benzoxaboroles and analogues were designed and synthesized for a structure-
activity-relationship (SAR) investigation to optimize the growth inhibitory activity against
Trypanosoma congolense (T. congolense) and Trypanosoma vivax (T. vivax) parasites. The study identified
4-fluorobenzyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate (5,
AN11736), which showed IC50 values of 0.15 nM against T. congolense and 1.3 nM against T. vivax, and
demonstrated 100% efficacy with a single dose of 10 mg/kg against both T. congolense and T. vivax in
mouse models of infection (IP dosing) and in the target animal, cattle, dosed intramuscularly.
AN11736 has been advanced to early development studies.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).Animal African Trypanosomiasis (AAT) is a fatal, parasitic wast-
ing disease of livestock and wild animals in Sub-Saharan Africa.1 It
is caused primarily by the two protozoan parasites Trypanosoma
congolense (T. congolense) and Trypanosoma vivax (T. vivax), which
are transmitted by tsetse flies.1 AAT is responsible for 3 million cat-
tle deaths annually and costs African livestock farmers approxi-
mately US$ 1–5 billion per year.2 The current standard-of-care
drugs, such as diminazene aceturate, isometamidium and homid-
ium chloride, have been in use for several decades and are often
ineffective with drug resistance becoming an increasing concern.1
No new trypanocides have been approved for use in cattle for
many years. Initial screening of the Anacor Pharmaceuticals library
of novel boron-containing compounds identified an active com-
pound (1, Fig. 1), which had an IC50 = 5 nM against T. congolense
and 69 nM against T. vivax while its enantiomer was much lessactive. A quick and simple modification on the amino acid side
chain with an isopropyl group generated 2 (Fig. 1) with improved
in vitro potency (IC50 = 2 nM against both T. congolense and T.
vivax). This encouraging result prompted us to investigate this
chemical series further. We designed and synthesized a series of
novel benzoxaboroles (3–71, Figs. 2–8) to optimize anti-parasitic
activity, physicochemical and in vitro ADME properties, and the
pharmacokinetic profile. Specifically, these molecules were
designed to examine the effects of oxaborole 3-substituent varia-
tion (3 vs 2, Figs. 1 and 2), oxaborole 7-substituent variation (4
vs 2, Figs. 1 and 2; 5 vs 20–27, Fig. 4), substituent changes on
the benzyl group (5–19, Fig. 3), modification of the amino acid
(28–32, Fig. 5), heteroaromatic methyl esters (33–48, Fig. 6), intro-
duction of water-solubilizing scaffolds to the benzyl group (49–54,
Fig. 7) and aliphatic esters (55–71, Fig. 8). Herein, we report the
synthesis and antiparasitic activity against T. congolense and T.
vivax of these novel compounds.
Compounds 1–71 were convergently synthesized from three
building blocks: the left side alcohols (72), amino acid linkers
Fig. 1. Chemical structures of early hits (1 and 2).
Fig. 2. Structures of benzoxaboroles with additional 3,3-Me2 (3) or 7-Me (4)
modification as compared to analog 2.
Fig. 3. Structures of benzoxaboroles with variation of substituents on the benzyl
ring (5–19) as compared to analog 4.
Fig. 4. Structures of benzoxaboroles with variation of 7-substituents on the
benzene ring (20–27) as compared to analog 5.
 
Fig. 5. Structures of benzoxaboroles with variation on the amino acid side chain
(28–32) as compared to analog 5.
 
Fig. 6. Structures of benzoxaboroles with variation of the left side arylmethyl
groups (33–48) as compared to analog 5.
 
Fig. 7. Structures of benzoxaboroles with water-solubilizing scaffolds on the benzyl
ring (49–54) as compared to analog 5.
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thetic route is shown in Scheme 1. Reaction of alcohols 72 with N-
Boc protected amino acids 73 gave ester intermediates 74, which
were treated with dry hydrogen chloride to generate ester amine
salts 75. Condensation of these amine salts 75 with benzoxaborole
6-carboxylic acids 76 provided the final compounds 1–71.
Scheme 2 illustrates the synthesis of 1-hydroxy-7-methyl-1,3-
dihydrobenzo[c][1,2]oxaborole-6-carboxylic acid (83) as an exam-
ple of key boron intermediates. Esterification of the acid 77 pro-
duced the ester 78, which was formylated to yield 79. Treatment
of 79 with trifluoromethyl sulfonyl anhydride afforded the triflate
compound 80, which was converted to the pinacol boron interme-
diate 81. Reduction of 81 and subsequent cyclization under aque-
ous acidic conditions generated the benzoxaborole ester 82.
Hydrolysis of the ester group in 82 afforded the acid 83. The exper-
imental procedures for the synthesis of 5 are described in the ref-
erence and note section.5
Activity of compounds 1–71 against T. congolense and T. vivax
was determined using the whole cell assays as described 6 and
their IC50 values are summarized in Table 1.
Lead compound 2 exhibited an IC50 of 2 nM against both T. con-
golense and T. vivax. The 3,3-dimethyl analog 3 was essentially
inactive (IC50 = 2580 nM against T. c. and 9190 nM against T. v.)
but better activity was observed for the 7-methyl analog 4 (IC50
Table 1
Activity of compounds 1–71 against T. congolense (T. c.) and T. vivax (T. v.).a
Compound IC50 (nM) Compound IC50 (nM)
T. c. T. v. T. c. T. v.
1 4.9 69 37 0.78 0.50
2 2.0 2.0 38 0.68 0.31
3 2580 9190 39 0.57 0.24
4 0.46 0.79 40 0.27 0.50
5 0.14 1.3 41 0.78 0.11
6 0.47 2.9 42 0.20 0.19
7 0.59 0.10 43 0.062 NTb
8 0.28 0.07 44 5000 980
9 0.18 0.10 45 0.37 0.33
10 0.22 2.7 46 0.42 0.24
11 0.16 24 47 0.20 0.081
12 0.31 19 48 <0.005 0.71
13 0.23 0.04 49 0.39 68
14 0.10 0.06 50 0.32 0.48
15 0.15 0.05 51 0.25 0.21
16 0.08 0.07 52 1.3 0.29
17 0.21 0.04 53 0.51 0.35
18 0.20 0.06 54 1.0 0.37
19 0.61 0.44 55 4.2 3.3
20 3.0 1.0 56 5.2 14
21 28 NTb 57 0.46 0.26
22 0.67 0.92 58 0.66 0.69
23 37 51 59 0.70 0.52
24 0.11 0.05 60 <0.005 0.78
25 3.0 4.7 61 0.36 0.21
26 2.3 0.05 62 0.38 0.16
27 3.9 0.71 63 0.39 0.09
28 0.12 0.38 64 2.3 0.78
29 0.26 0.10 65 9.4 1.2
30 0.09 0.25 66 5.9 4.1
31 0.13 18 67 0.43 0.79
32 0.45 2.5 68 1.8 37
33 0.28 26 69 0.47 1.6
34 0.14 0.07 70 0.34 2.28
35 0.15 0.09 71 0.2 0.14
36 0.26 0.14
a Experimental procedures are described in the reference and note section.6
b NT = Not tested.
 
Fig. 8. Structures of benzoxaboroles with variation of the left side aliphatic ester
groups (55–71) as compared to analog 5.
Scheme 1. General route for syntheses of 1–71. Reagents and conditions: (a) DCC,
DMAP, DCM, 0–20 C, 16 h; (b) HCl/EtOAc, 20 C, 5 h; (c) HOBt, EDCI, TEA, DCM, 0–
20 C, 15 h.
Scheme 2. Synthetic route for preparation of 83. Reagents and conditions: (a)
H2SO4, EtOH, reflux, 24 h; (b) MgCl2, (CH2O)n, TEA, THF, reflux, 14 h; (c) Tf2O,
pyridine, DMAP, DCM, 0–15 C, 1 h; (d) Pin2B2, KOAc, Pd(dppf)Cl2, 1,4-dioxane, N2,
85 C, 15 h; (e) NaBH4, MeOH, THF, 0–15 C, 1 h, then HCl, H2O; (f) NaOH,H2O, 40 C,
3 h, then HCl for acidification.
8 T. Akama et al. / Bioorganic & Medicinal Chemistry Letters 28 (2018) 6–10= 0.46 nM against T. c. and 0.79 nM against T. v.). We focused future
SAR development on compounds incorporating the 7-methyl
group, as in vivo activity of 4 was superior to that observed for 2
(vide infra). A wide range of substituents, such as halogens, trifluo-
romethyl, trifluoromethoxy, cyano and methylsulfonyl (5–19 in
Fig. 3) on the benzyl ring were introduced to examine their effects
on the antiparasitic activity. The majority of these fifteen com-
pounds, with exception of 11 and 12, were very potent showing
IC50 values around 1 nM (see Table 1). We next explored variation
of the substituent at the 7-position of benzoxaborole (20–27 in
Fig. 4). The difluoromethyl (22) and ethyl (24) analogs had similar
activity to that of 5, but the electron-withdrawing fluoro (21) and
trifluoromethyl (23) analogs were of significantly reduced potency.
The amino acid linker was also modified (Fig. 5), with the cyclo-
propyl (28), 2-hydroxyisopropyl (29), 2-fluoroisopropyl (30) and
spirocyclobutyl (32) analogs exhibiting potency similar to 5, but
the spirocyclopropyl analog (31) exhibited decreased activity
against T. v. parasite. Replacement of the 4-fluorophenyl in 5 with
various heteroaryl groups (33–48, Fig. 6) resulted in the excellent
activity in all cases except the NH-imidazole analog 44. Introduc-
tion of basic nitrogen-containing groups on the benzyl ester (49–
54, Fig. 7) provided compounds 50–54 that were generally similar
to 5. Lastly, aliphatic and heterocyclic esters (55–71, Fig. 8) weresynthesized and many of these had IC50 values less than 1 nM as
shown in Table 1.
T. Akama et al. / Bioorganic & Medicinal Chemistry Letters 28 (2018) 6–10 9Selected compounds were screened in both mouse and bovine
in vitro metabolic stability assays (mouse S9 and bovine S9), as
summarized in Table 2. These two species were chosen because
the primary in vivo assays were conducted in mice, and the target
animal of this research program is cattle. As shown in Table 2, out
of 36 compounds tested, 27 compounds had Clint < 10 mL/min/mg
protein in both mouse and bovine S9 assays suggesting moderate
to excellent in vitro metabolic stability. We evaluated the efficacy
of selected compounds in two in vivo mouse models of infection,
against T. congolense and T. vivax, respectively. Mice were infected
with either 1  105 T. c. parasites or 1  104 T. v. parasites, and then
treated with a test compound via intraperitoneal administration
for 1, 2 or 4 consecutive days. The mice were then monitored for
the presence of parasitemia for up to 60 days post treatment.7
We tested in T. c. model first, then followed up with T. v. for inter-
esting compounds. As shown in Table 2, the 7-methyl analog 4was
superior to the 7-unsubstituted analog 2 in both T. c. and T. v.
mouse models of infection. Of the 38 compounds tested with theTable 2
In vitro metabolic stability and in vivo mouse efficacy of selected compounds.a
Compound Clint (mL/min/mg protein) Efficacy in mouse modelb
Mouse S9 Bovine S9 T. c. T. v.
2 NTc NTc 0/5 (2  10) 5/5 (4  10)
1/5 (1  10)
4 NTc NTc 4/5 (2  10) 5/5 (2  10)
4/4 (1  10)
5 5.4 9.3 5/5 (2  10)
4/4 (1  10)
0/4 (1  5)
5/5 (2  10)
5/5 (1  10)
4/4 (1  10)
6 17 9.1 0/4 (1  10) NTc
8 7.9 5.6 4/4 (1  10)
0/4 (1  5)
4/4 (1  10)
14 9.1 2.7 0/4 (1  10) NTc
16 15 8.9 4/4 (2  10)
1/4 (1  10)
NTc
17 14 10 0/4 (1  10) NTc
18 9.7 3.1 1/4 (1  10) NTc
19 2.6 1.3 0/4 (1  10) NTc
20 1.5 1.3 0/5 (4  10) NTc
21 <1 <1 1/4 (2  10) 4/4 (2  10)
22 1.4 0.9 0/4 (1  10) NTc
24 21 23 1/4 (2  10) NTc
26 32 32 0/4 (1  10) NTc
29 <1 <1 0/4 (1  10) NTc
30 3.7 3.1 0/4 (1  10) NTc
31 <1 <1 0/4 (1  10) NTc
33 6.3 2.0 3/4 (1  10) 4/4 (1  10)
34 11.8 4.8 2/4 (1  10) 4/4 (1  10)
35 5.2 7.8 0/4 (1  10) NTc
39 1.6 3.9 0/4 (1  10) NTc
41 1.3 1.8 0/4 (1  10) NTc
46 7.4 7.0 1/4 (1  10) NTc
47 4.8 10 0/4 (1  10) NTc
48 4.0 23 1/4 (1  10) NTc
49 1.5 4.0 2/4 (1  10) 4/4 (1  10)
50 8.6 12.7 1/4 (1  10) 4/4 (1  10)
51 1.8 5.0 0/4 (1  10) 4/4 (1  10)
52 1.8 6.0 0/4 (1  10) NTc
53 5.4 6.8 0/4 (1  10) NTc
54 5.5 3.8 0/4 (1  10) NTc
55 <1 3.1 0/4 (1  10) NTc
62 10 20 2/4 (1  10) 4/4 (1  10)
63 0.9 1.5 1/4 (1  10) 4/4 (1  10)
69 0.7 0.6 1/4 (1  10) 1/4 (1  10)
70 1.5 0.3 1/4 (1  10) 4/4 (1  10)
71 6.4 8.1 3/4 (1  10) 4/4 (1  10)
a Methods for testing compound efficacy in mouse models are described in the
reference and note section.7
b The efficacy data in the table is presented as n/m (q  10), where n = number of
mice survived, m = total number of mice in the study group, q = how many time
dosed, and 10 = 10 mg/kg.
c NT = Not tested.in vivo mouse models, seven compounds (5, 8, 33, 34, 49, 62 and
71) demonstrated 50% curative efficacy in the T. c.-infected
mouse model and 100% curative efficacy in the T. v.-infected mouse
model, when tested as a single dose of 10 mg/kg. To select further
from these seven compounds, four (5, 8, 33 and 71) had75% cura-
tive efficacy in the T. c.-infected mouse model at a single dose of 10
mg/kg, and two (5 and 8) showed 100% curative efficacy. These two
compounds were further tested at a single 5 mg/kg dose, but were
unable to cure the T. c.-infected mice. We selected compound 5
(AN11736) to progress to exploratory studies to determine the effi-
cacy and safety in a preliminary formulation against induced infec-
tions of T. vivax and T. congolense in cattle.8 AN11736
demonstrated 100% curative efficacy with a single intramuscular
injection of 10 mg/kg against both T. congolense and T. vivax in
cattle.
In summary, a novel series of L-valinate amide benzoxaboroles
was discovered to be active against T. congolense and T. vivax,
which are the main causative agents of Animal African Trypanoso-
miasis (AAT) in cattle. Two compounds (5 and 8) showed 100%
curative efficacy in both T. c.- and T. v.-infected mice with a single
dose of 10 mg/kg. Compound 5 (AN11736) demonstrated 100%
curative efficacy with a single IM dose of 10 mg/kg against both
T. congolense and T. vivax in cattle for a duration of 100 days.
AN11736, as a novel chemical entity, was selected as a potential
developmental candidate for the treatment of AAT.
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5. Experimental procedures for the synthesis of 4-fluorobenzyl (1-hydroxy-7-methyl-
1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate (5, AN11736): To a
solution of 77 (1.65 kg, 10.8 mol) in EtOH (6.50 L) was added conc. H2SO4
(326 g, 3.25 mol). The reaction mixture was stirred at 105 C for 24 h. TLC (thin
layer chromatography) showed the starting material was consumed completely.
The mixture was cooled to 15 C and concentrated. The residue was poured into
aqueous 2 M NaHCO3 (3 L) and the solid was filtered off. The filtrate was
concentrated to give 78 (1.75 kg, yield 90%) as a brown solid. 1H NMR (400 MHz,
CDCl3): d 7.41 (d, J = 7.9 Hz, 1H), 7.11 (t, J = 7.9 Hz, 1H), 6.94 (d, J = 7.9 Hz, 1H),
4.58 (br s, 1H), 4.37 (q, J = 7.4 Hz, 2H), 2.46 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H). To a
solution of 78 (800 g, 4.44 mol) in THF (6.50 L) were added MgCl2 (634 g, 6.66
mol), TEA (1.80 kg, 17.8 mol) and (HCHO)n (600 g, 6.66 mol). The mixture was
immediately heated to 90 C and was stirred for 14 h. The reaction mixture was
cooled to 15 C. To it were added ice H2O (3 L) and then 12 N HCl (1.5 L) slowly.
The mixture was stirred for 0.5 h and then extracted with EtOAc (2 L). The
combined organic layer was washed with sat. NaHCO3 to neutral, dried over
Na2SO4, filtered and concentrated under reduced pressure to give crude 79 (880
g) as a brown oil. 1H NMR (400 MHz, CDCl3): d 11.40 (s, 1H), 9.93 (s, 1H), 7.46 (d,
J = 7.6 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 4.40 (q, J = 7.4 Hz, 2H), 2.44 (s, 3H), 1.41 (t,
J = 7.1 Hz, 3H). To a solution of 79 (900 g, 4.32 mol) in DCM (7.56 L) were added
pyridine (1.02 kg, 12.9 mol) and DMAP (27 g, 221 mmol). The mixture was
cooled to 0 C and Tf2O (1.60 kg, 5.66 mol) was added dropwise. The reaction
mixture was warmed to 15 C and stirred for 1 h. The mixture was quenched
with water (7.65 L) and then extracted with DCM (2  7.65 L). The combined
organic layer was washed with water (2 L), dried over Na2SO4, filtered and
concentrated under reduced pressure to give 80 (685 g, 47%) as a light yellow oil.
1H NMR (400 MHz, CDCl3): d 10.27 (s, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.91–7.87 (m,
1H), 4.43 (q, J = 7.0 Hz, 2H), 2.64 (s, 3H), 1.43 (t, J = 7.3 Hz, 3H). To a solution of
80 (1.00 kg, 2.94 mol), bis(pinacolato)diboron (1.12 kg, 4.41 mol) and KOAc
(573 g, 5.84 mol) in 1,4-dioxane (6.50 L) was added Pd(dppf)Cl2CH2Cl2 (150 g,
184 mmol). The mixture was stirred at 85 C for 15 h under N2. The mixture was
10 T. Akama et al. / Bioorganic & Medicinal Chemistry Letters 28 (2018) 6–10cooled to 15 C, filtered and concentrated to give the crude product. The residue
was purified by column chromatography (SiO2, petroleum ether/ethyl acetate =
40/1 to 4:1) to give crude 81 (942 g) as a yellow oil. To a solution of 81 (1.20 kg,
3.77 mol) in MeOH (300 mL) and THF (6 L) was added NaBH4 (80 g, 2.11 mol) in
portions at 0 C. Then the reaction mixture was stirred at 15 C for 1 h. HPLC
showed 81was consumed completely. The reaction solution was adjusted to pH
= 4 with 2 M HCl. The organic layer was removed in vacuum and the mixture
was filtered. The cake was washed with petroleum ether (5 L) and dried in
vacuum to give 82 (665 g, 80%) as a white solid. 1H NMR (400 MHz, DMSO-d6): d
9.18 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 5.00 (s, 2H), 4.30 (q, J
= 7.0 Hz, 2H), 2.68 (s, 3H), 1.33 (t, J = 7.0 Hz, 3H). To a mixture of 82 (867 g, 3.94
mol) in H2O (5 L) was added NaOH (394 g, 9.85 mol) in one portion. The solution
was heated at 40 C for 3 h. HPLC showed 82 was consumed completely. This
batch was worked-up together with the other batches and acidified with 2 N HCl
to pH = 2. The solid was filtered and washed with H2O (10 L). The cake was dried
to give 83 (2.00 kg, yield 87%) as a white solid. 1H NMR (400 MHz, DMSO-d6): d
12.75 (s, 1H), 9.13 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 4.98 (s,
2H), 2.68 (s, 3H); HPLC purity: 100% at both 220 nm and 254 nm; MS (ESI+):m/z
= 193 (M+1). To a solution of 4-fluorobenzylalcohol (72, R1 = 4-fluorobenzyl,
290 g, 2.30 mol, 248.10 mL) and N-Boc-(S)-valine (73, R2 = isopropyl, R3 = H, 500
g, 2.30 mol) in dry DCM (6.0 L) were added DCC (854 g, 4.14 mol, 838 mL) and
DMAP (39.36 g, 322.19 mmol). The reaction mixture was stirred at 25 C for 15
h. The mixture was filtered and washed with DCM (2 L) and concentrated to give
the crude product. The residue was purified by column chromatography (SiO2,
petroleum ether/ethyl acetate = 50:1 to 10:1) to give 4-fluorobenzyl (tert-
butoxycarbonyl)-L-valinate (74, R1 = 4-fluorobenzyl, R2 = isopropyl, R3 = H, 708
g, 95% yield) as a white solid. 1H NMR (400 MHz, CDCl3): d 7.35 (dd, J = 8.2 & 5.5
Hz, 2H), 7.05 (t, J = 8.6 Hz, 2H), 5.19–5.08 (m, 2H), 5.01 (d, J = 8.4 Hz, 1H), 4.25
(dd, J = 8.4 & 4.4 Hz, 1H), 2.13 (dd, J = 11.9 & 6.2 Hz, 1H), 1.44 (s, 9H), 0.93 (d, J =
7.1 Hz, 3H), 0.84 (d, J = 7.1 Hz, 3H). The mixture of 4-fluorobenzyl (tert-
butoxycarbonyl)-L-valinate (74, R1 = 4-fluorobenzyl, R2 = isopropyl, R3 = H,
1.06 kg, 3.26 mol) in HCl/EtOAc (6.0 L) was stirred at 25 C for 14 h. The
solvent was removed under reduced pressure to give 4-fluorobenzyl L-valinate
hydrochloride (75, R1 = 4-fluorobenzyl, R2 = isopropyl, R3 = H, 780 g, 91% yield)
was obtained as a white solid. 1H NMR (400 MHz, CDCl3): d 8.90 (br. s, 3H), 7.37
(dd, J = 8.2 & 5.5 Hz, 2H), 7.03 (t, J = 8.4 Hz, 2H), 5.29–5.10 (m, 2H), 3.95 (br, s,
1H), 2.44 (dd, J = 11.0 & 6.6 Hz, 1H), 1.08 (dd, J = 10.1 & 7.1 Hz, 6H). To the
mixture of 83 (150 mg, 0.77 mmol), 75 (203 mg, 0.77 mmol) and DIEA (0.4 mL,
2.33 mmol) in DMF was added HATU (325 mg, 0.86 mmol). The mixture was
stirred at rt for 3 h. The crude product was purified by preparative TLC and
preparative HPLC to get the final product 5 (AN11736, 125 mg, 40% yield). 1H
NMR (400 MHz, DMSO-d6): d 9.03 (s, 1H), 8.57 (d, J = 7.2 Hz, 1H), 7.47–7.43 (m,
2H), 7.33 (d, J = 7.6 Hz, 1H), 7.23–7.18 (m, 3H), 5.21 (d, J = 12.4 Hz, 1H), 5.11 (d, J
= 12.4 Hz, 1H), 4.96 (s, 2H), 4.33 (t, J = 7.2 Hz, 1H), 2.42 (s, 3H), 2.19-2.10 (m, 1H),
0.94 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H); HPLC purity: 100% at both 220 nm
and 254 nm; MS (ESI+): m/z = 400 (M+1).
6. Assay methods for determination of T. c. and T. v. IC50 values: Bloodstream-form
Trypanosoma congolense (T. congolense IL-3000 strain) were cultured in 24-wellplates at 34 C and 5% CO2. Culture media consisted of complete HMI-9 (IMDM)
with 20% bovine serum. To ensure log growth phase, trypanosomes were sub-
cultured at appropriate dilutions every 2–3 days. Bloodstream form
Trypanosoma vivax (T. vivax) cannot be cultured axenically, therefore
trypanosomes (T. vivax STIB719/ILRAD 560 strain) were harvested from a
highly parasitemia mouse via cardiac puncture and used directly in the ex vivo
drug sensitivity assay on the same day. IC50 determination was carried out using
the Alamar Blue assay for T. congolense (72 h in vitro assay) and modified slightly
for T. vivax (48 h ex vivo assay). Parasite starting concentrations of 2  105 (T. c.)
and 4  105 (T. v.) were calculated respectively, using a cell analyzer system or
haemo-cytometer, followed by quantification at 536 nm excitation and 588 nm
emission wavelengths using a flow cytometer reader. Test compounds were
prepared as 10 mg/mL DMSO stocks for each assay run. Compounds were
assayed in at least three separate, independent test runs and an 11-point
dilution curve was used to determine the IC50 values. Data points were averaged
to generate sigmoidal dose-response curves and IC50 values were determined
using Softmax Pro 5.2 software.
7. Methods for testing compound efficacy in mouse models: In vivo mouse efficacy
studies were performed at the Swiss TPH, using established mouse models of
infection for T. c. and T. v. NMRI female mice were independently infected either
with 1  105 T. c. parasites/mouse (STIB736/IL1180 strain) or 1  104 T. v.
parasites/mouse (STIB719/ILRAD560 strain) using an intraperitoneal route.
Parasitemia was allowed to develop over 7 days (T. c.) or 3 days (T. v.),
respectively, before treatment was administered. Compounds were
administered via intraperitoneal injection in 10% DMSO/water. Four mice were
used per treatment group. Mice were monitored for the presence of
trypanosomes, via tail blood examination microscopically with twice-per-
week parasitemia checks for 60 days post treatment. Parasitemia was graded
on a scale of 0–3, with 0 indicating no trypanosomes seen in 20 fields of view, 1
indicating the presence of 1–5 trypanosomes per field, 2 indicating the presence
of 6–20 trypanosomes per field and 3 indicating greater than 20 trypanosomes
per field. Mice scoring 2 or 3 were immediately euthanized. After 60 days,
aparasitemic mice were considered cured. Untreated control mice survive on
average for 10 and 6 days post infection for T. c. and T. v., respectively. All in vivo
mouse experiments were conducted in accordance with the strict guidelines set
out by the Swiss Federal Veterinary Office, under the ethical approval of license
number #2813.
8. Method for testing compound efficacy in cattle: The cattle studies were conducted
in accordance with the method described for cattle by Eisler et al. (2001) in
studies conducted in fly-proof facilities and using T. congolense and T. vivax
isolates that had previously been confirmed resistant in cattle to diminazine (7
mg/kg live weight) and/or isometamidium (1 mg/kg live weight). Cattle studies
included negative (saline) controls, all assessments were made for 100 days post
treatment (unless animals relapsed sooner) and were conducted by staff blinded
(masked) to allocation of animals to treatment groups and in accordance with
the principles of veterinary good clinical practice (VICH, 2000).
